ArticleEndocrinology, diabetes & metabolism2026
Association Between Impaired Fasting Glucose and Adverse Outcomes in Patients Treated With Peritoneal Dialysis: A Retrospective Study From Southern China.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of this research was to explore the relationship between impaired fasting glucose (IFG) and adverse clinical outcomes in a southern Chinese population receiving peritoneal dialysis (PD) therapy.
methodsParticipants who underwent PD therapy for > 3 months during January 1, 2004 to July 27, 2021, across four centers were included. Baseline data were collected in the initial 3 months of PD therapy. We defined IFG using World Health Organization criteria (IFG-WHO: 6.1-6.9 mmol/L). The adverse outcomes included all-cause mortality, cardiovascular mortality and cardiovascular events. Kaplan-Meier survival analyses and Cox regression models were utilized to assess the associations between IFG and adverse outcomes.
resultsA total of 2345 PD patients were included, with 666 (28.4%) diagnosed with diabetes and 209 (8.9%) with IFG. Over an average follow-up duration of 32 months (25th-75th, 15-54), 276 (11.8%) deaths occurred, including 186 (7.9%) cardiovascular mortality, and 356 (15.2%) cardiovascular events were documented. Kaplan-Meier survival curves showed that patients with IFG had a significantly higher risk of cardiovascular mortality than those with normoglycemia. Cox multivariate analysis showed that IFG was an independent risk factor for cardiovascular mortality (HR = 1.735; 95% CI: 1.023-2.944) after adjusting for confounders. No significant differences were observed in all-cause mortality or cardiovascular event risks between groups.
conclusionsIFG was independently associated with increased cardiovascular mortality in PD patients. These findings highlight the need for glycemic monitoring in non-diabetic PD populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.